Sponsor:
Ohio State University Comprehensive Cancer Center
Code:
NCT05677802
Conditions
Anatomic Stage I Breast Cancer AJCC v8
Anatomic Stage II Breast Cancer AJCC v8
Anatomic Stage III Breast Cancer AJCC v8
HER2-Negative Breast Carcinoma
Hormone Receptor-Negative Breast Carcinoma
Eligibility Criteria
Sex: Female
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Biospecimen Collection
Medical Chart Review
Stress Management Therapy
Survey Administration
Brief summary:
Conditions
Anatomic Stage I Breast Cancer AJCC v8
Anatomic Stage II Breast Cancer AJCC v8
Anatomic Stage III Breast Cancer AJCC v8
HER2-Negative Breast Carcinoma
Hormone Receptor-Negative Breast Carcinoma
Study ID
NCT05677802
Start date
Dec 14, 2022
Status verified date
May, 2026
Completion date
Jun 30, 2027
Anticipated
Primary completion date
Dec 31, 2026
Anticipated
Eligibility Criteria
Sex: Female
Age: 18+
Healthy Volunteers: Not accepted
Enrollment
40 participants
Anticipated
Intervention Model
Single group
Primary purpose
Health Services Research
Arms
experimental: Health Services Research (stress management therapy)
Interventions
Biospecimen Collection
Medical Chart Review
Stress Management Therapy
Survey Administration
Primary outcome measure
Central contacts
Locations
Ohio State University Comprehensive Cancer Center
Recruiting
Columbus, Ohio, United States, 43210
Contacts
Principal Investigator:
Samilia Obeng-Gyasi, MD, MPH
Sponsor
Ohio State University Comprehensive Cancer Center
Last update posted
Jun 29, 2026
Last verified
May, 2026
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Ohio State University Comprehensive Cancer Center on 2026-06-29.